Drugs / vatreptacog alfa (activated)
vatreptacog alfa (activated)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00822185 | Jan → Jul 2009 | hemorrhagic disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00486278 | Jun 2007 → Jun 2010 | hemophilia A, hemophilia B | Novo Nordisk A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2012-09-28 | Novo Nordisk A/S | Results Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results novonordisk.com ↗
Novo Nordisk today announced the decision to discontinue the development of vatreptacog alfa, a fast-acting recombinant factor VIIa analogue for haemophilia patients with inhibitors. |
| 2012-09-28 | Novo Nordisk A/S | Results Novo Nordisk A/S: Novo Nordisk indstiller udviklingen af vatreptacog alfa efter analyse af fase 3-resultater novonordisk.com ↗
Novo Nordisk meddelte i dag, at det er besluttet at indstille udviklingen af den hurtigtvirkende rekombinante faktor VIIa-analog, vatreptacog alfa, til hæmofilipatienter med inhibitorer. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-09-28 | Novo Nordisk A/S | Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results novonordisk.com ↗ |
| 2012-09-28 | Novo Nordisk A/S | Novo Nordisk A/S: Novo Nordisk indstiller udviklingen af vatreptacog alfa efter analyse af fase 3-resultater novonordisk.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vatreptacog alfa (activated) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00486278 ↗ |
| Known as | NN1731 | “A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated]) was developed to provide safe, rapid and sustained resolution of bleeds in patients with hemophilia and...” PMID 22470921 ↗ Jan 20121“activated recombinant human coagulation factor VII analogue (NN1731, vatreptacog alfa (activated))” NCT00822185 ↗ |
| Known as | vatreptacog alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00822185 ↗ |
| Known as | Vatreptacog alfa (activada) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108322 ↗ |
| Known as | Vatreptacog alfa (active) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108322 ↗ |
| Modality | Protein / enzyme biologic | “A recombinant factor VIIa analog (NN1731; vatreptacog alfa [activated])” PMID 22470921 ↗ Jan 2012 |
| Route | Intravenous | “5 mcg/kg, injected i.v.” NCT00486278 ↗ |